Skip to main content
. 2023 Nov 10;102(45):e35950. doi: 10.1097/MD.0000000000035950

Table 2.

Best responses with atezolizumab plus bevacizumab (65 patients).

Response n %
Complete response (CR) 1 1.5
Partial response (PR) 23 35.4
Stable disease (SD) 24 36.9
Progressive disease (PD) 17 26.2
Objective response rate (CR + PR) 24 36.9
Disease control rate (CR + PR + SD) 48 73.8